イスラエル - 英語 - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - chewable tablets - lanthanum as carbonate hydrate 1000 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

シンガポール - 英語 - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - anti inhibitor coagulant complex - injection, powder, for solution - 50 u/ml - anti inhibitor coagulant complex 50 u/ml

シンガポール - 英語 - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - anti inhibitor coagulant complex - injection, powder, for solution - 25 u/ml - anti inhibitor coagulant complex 25 u/ml

欧州連合 - 英語 - EMA (European Medicines Agency)

takeda manufacturing austria ag - c1 inhibitor (human) - angioedemas, hereditary - c1-inhibitor, plasma derived, drugs used in hereditary angioedema - treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2 years old and above) with hereditary angioedema (hae).routine prevention of angioedema attacks in adults, adolescents and children (6 years old and above) with severe and recurrent attacks of hereditary angioedema (hae), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.

欧州連合 - 英語 - EMA (European Medicines Agency)

takeda gmbh - pantoprazole - gastroesophageal reflux - proton pump inhibitors - short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.

欧州連合 - 英語 - EMA (European Medicines Agency)

takeda pharma a/s - azilsartan medoxomil - hypertension - agents acting on the renin-angiotensin system - edarbi is indicated for the treatment of essential hypertension in adults.

欧州連合 - 英語 - EMA (European Medicines Agency)

takeda pharma a/s - metformin hydrochloride, pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - glubrava is indicated as second line treatment of type-2-diabetes-mellitus adult patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

欧州連合 - 英語 - EMA (European Medicines Agency)

takeda pharma a/s - pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.after initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

欧州連合 - 英語 - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin, pioglitazone - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - incresync is indicated as a second- or third-line treatment in adult patients aged 18 years and older with type-2 diabetes mellitus: , as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance;, in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone. , in addition, incresync can be used to replace separate tablets of alogliptin and pioglitazone in those adult patients aged 18 years and older with type-2 diabetes mellitus already being treated with this combination. after initiation of therapy with incresync, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, incresync should be discontinued. in light of potential risks with prolonged pioglitazone therapy, prescribers should confirm at subsequent routine reviews that the benefit of incresync is maintained (see section 4.4).,

欧州連合 - 英語 - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - guanfacine hydrochloride - attention deficit disorder with hyperactivity - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv must be used as a part of a comprehensive adhd treatment programme, typically including psychological, educational and social measures.,